Dyadic International, Inc. announced positive results from third party analytical testing of the company?s animal-free recombinant serum albumin. Using Dyadic?s proprietary filamentous fungal based microbial protein production platforms, the Company has been able to successfully develop stable cell lines to produce animal-free recombinant bovine serum albumin and recombinant human serum albumin at high levels. Initial independent analytical testing of the Company?s recombinant bovine albumin demonstrated it is structurally equivalent to commercial animal derived product.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.48 USD | -6.33% | -15.91% | -8.07% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-8.07% | 43.27M | |
+19.41% | 45.51B | |
+38.65% | 39.36B | |
-8.62% | 38.52B | |
+26.95% | 30.74B | |
-13.50% | 26.03B | |
+10.74% | 25.92B | |
+44.87% | 14.13B | |
+34.36% | 12.73B | |
-7.14% | 11.29B |
- Stock Market
- Equities
- DYAI Stock
- News Dyadic International, Inc.
- Dyadic Announces Positive Results from Third Party Analytical Testing of Animal-Free Recombinant Serum Albumin